Table of Contents Table of Contents
Previous Page  72 / 916 Next Page
Show Menu
Previous Page 72 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S53–S68


Identifying service and care needs

from the users’ perspective in

treatment-resistant schizophrenia

K. Rubinstein

1 , 2 , 3


The Gertner Institute of Epidemiology and Health Policy Research,



Psychiatric Division, Sheba Medical Center, Israel


Tel-Aviv University, The Sackler School of Medicine, Israel

Exploring service and care needs of patients with treatment-

resistant schizophrenia is necessary for a better understanding of

their psychosocial functioning, in order to develop rehabilitation

goals as well as to provide them with better care.

m-RESIST is an innovative project aimed to empower patients

with resistant schizophrenia, to personalize treatment by integrat-

ing pharmacological and psycho-social approaches, and to develop

knowledge related to the illness using predictive models designed

to exploit historical and real-time data, based on environmental

factors and treatment outcomes.

m-RESIST is a system based on computer and cellular applications

and wearable computing devices. The system will serve patients,

caregivers and clinicians, and include the following functions:

Information, Assessment, Monitoring, Communication, and Inter-


The first step in the development process included definition of

the end user needs and preferences, in order to involve users in

the design of the system. Outpatients with treatment-resistant

schizophrenia, informal carers (relatives), and clinicians were

included in the sample. There were a total of 9 focus groups, 3

in each pilot country. Each group was composed of one of the

participant profiles. Additionally, 35 individual interviews were

performed, which were unevenly distributed throughout the 3


The current workshop section will present the outcomes of this

process: perceived advantages and disadvantages of the techno-

logical solution, as well as conclusions for further development. In

addition, methodological issues, future challenges, relevant for the

evolution of the m-RESIST project, in particular, as well as techno-

logical developments in the field of mental health, in general, will

be discussed.

1 Disclosure of interest

The author has not supplied his decla-

ration of competing interest.


m-RESIST project as an example of

m-health approach in schizophrenia:

Content, aims and realization

I. Corripio

Barcelona, Spain

This communication aims to present m-RESIST, the first mHealth

program for patients with treatment resistant schizophrenia (TRS).

The main objective of this European project is to develop an inter-

vention programme to allow TRS patients to self-manage their

condition, which is associated with persistent positive symptoma-

tology, extensive periods of hospital care, and a greater risk of

excess mortality and multi-morbidity.

m-RESIST could offer a new tool for mental health professionals

to better monitor TRS patients, providing a tailored and optimized

therapeutic intervention. In this sense, m-RESIST will develop and

validate amHealth tool aimed to reduce the severity of episodes and

further complications. Moreover, this tool will involve and promote

a proactive role of patients and caregivers in the therapeutic pro-

cess, promoting an active and collaborative role with the medical

team in the treatment decision-making procedure.

m-RESIST intervention, will integrate: (1) a sensor data analysis

module, which will process data coming from smart phone and

wearable devices, providing passive information such as move-

ment or social activity; (2) a predictive modeling engine, which

will enable prediction of clinically significant events, such as hos-

pitalization, risk behaviors and social isolation; and (3) a clinical

decision support system (CDSS), which will provide the users

with necessary information to support health-related and clinical


The pilots of this project will take place in Tel-Aviv, Budapest

and Barcelona during May, June and July of 2017. Although cost-

effectiveness variables will also be measured, the main assessment

will be focused on acceptability, usability, satisfaction, empower-

ment and quality of life outcomes.

Disclosure of interest

The author has not supplied his declaration

of competing interest.